BidaskClub Upgrades Momenta Pharmaceuticals (NASDAQ:MNTA) to Buy

Momenta Pharmaceuticals (NASDAQ:MNTA) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a report released on Tuesday, January 9th.

Several other equities research analysts have also recently commented on the stock. Zacks Investment Research cut shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, December 4th. Stifel Nicolaus reiterated a “hold” rating and issued a $15.00 price target (down from $22.00) on shares of Momenta Pharmaceuticals in a research note on Wednesday, October 4th. Barclays restated an “equal weight” rating and set a $16.00 price objective (down from $17.00) on shares of Momenta Pharmaceuticals in a research note on Wednesday, October 4th. Goldman Sachs Group restated a “neutral” rating and set a $14.00 price objective (down from $18.00) on shares of Momenta Pharmaceuticals in a research note on Thursday, October 5th. Finally, Cowen set a $15.00 price objective on shares of Momenta Pharmaceuticals and gave the stock a “hold” rating in a research note on Wednesday, November 1st. Two research analysts have rated the stock with a sell rating and ten have given a hold rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $15.00.

Shares of Momenta Pharmaceuticals (NASDAQ MNTA) traded up $1.25 on Tuesday, reaching $16.40. 2,336,034 shares of the company’s stock were exchanged, compared to its average volume of 751,996. The company has a market capitalization of $1,157.26, a PE ratio of -20.50 and a beta of 1.66. Momenta Pharmaceuticals has a 1 year low of $11.85 and a 1 year high of $19.90.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.03. The company had revenue of $24.09 million for the quarter, compared to analysts’ expectations of $29.58 million. Momenta Pharmaceuticals had a negative net margin of 55.61% and a negative return on equity of 16.20%. The business’s quarterly revenue was down 17.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.26) earnings per share. research analysts predict that Momenta Pharmaceuticals will post -1.16 earnings per share for the current year.

In other news, Director Elizabeth Stoner sold 5,500 shares of the stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $13.10, for a total transaction of $72,050.00. Following the completion of the sale, the director now directly owns 13,240 shares in the company, valued at $173,444. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Craig A. Wheeler sold 4,116 shares of the stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $13.35, for a total transaction of $54,948.60. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 49,505 shares of company stock valued at $685,923. Corporate insiders own 4.40% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of MNTA. Ameritas Investment Partners Inc. increased its position in shares of Momenta Pharmaceuticals by 14.9% during the second quarter. Ameritas Investment Partners Inc. now owns 6,446 shares of the biotechnology company’s stock worth $109,000 after buying an additional 834 shares during the period. Pinebridge Investments L.P. increased its position in shares of Momenta Pharmaceuticals by 4.3% during the second quarter. Pinebridge Investments L.P. now owns 8,798 shares of the biotechnology company’s stock worth $149,000 after buying an additional 363 shares during the period. Profund Advisors LLC increased its position in shares of Momenta Pharmaceuticals by 13.1% during the second quarter. Profund Advisors LLC now owns 13,172 shares of the biotechnology company’s stock worth $223,000 after buying an additional 1,530 shares during the period. Citigroup Inc. boosted its stake in Momenta Pharmaceuticals by 263.2% during the second quarter. Citigroup Inc. now owns 13,736 shares of the biotechnology company’s stock worth $232,000 after acquiring an additional 9,954 shares in the last quarter. Finally, Piedmont Investment Advisors LLC bought a new position in Momenta Pharmaceuticals during the second quarter worth $244,000. Institutional investors own 93.40% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.thelincolnianonline.com/2018/01/20/momenta-pharmaceuticals-mnta-lifted-to-buy-at-bidaskclub-updated.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Analyst Recommendations for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply